Feds Toughen Warning for Depo-Provera

Novembere 19, 2004

Birth Control • FDA Approves Generic 'Plan B' Pill • Over-the-Counter Contraceptive Pill May Not Work • Ortho-Evra Patch Should Be Withdrawn: Public Citizen • Contraceptive Pill May Help Conception • Birth Control Pill Linked to Heart Disease • New Contraceptive Eliminates Women’s Periods • FDA Approves OTC Sales of Plan B • Wal-Mart Agrees to Stock Plan B in Connecticut Stores • Wal-Mart to Begin Dispensing "Morning After" Pill This Week • FDA: Birth Control Patch Needs More Study • Little Risk with Today's IUDs • Wal-Mart May Stock "Emergency" Contraceptives • New Warning Labels for Ortho Evra Contraceptive Patch • Feds Toughen Warning for Depo-Provera

The Food and Drug Administration is adding a "black box" warning to Depo-Provera labels, warning that prolonged use may result in the loss of bone density. The injectable drug is used to prevent pregnancy.

The black box warning for Depo-Provera highlights that prolonged use of the Pfizer drug may result in significant loss of bone density, and that the loss is greater the longer the drug is administered. This bone density loss may not be completely reversible after discontinuation of the drug.

Thus the warning states that a woman should only use Depo-Provera Contraceptive Injection as a long-term birth control method (for example, longer than two years) if other birth control methods are inadequate for her.

Black box warnings are designed to highlight special problems, particularly those that are serious, and to give health care professionals a clear understanding of a potential medical complication associated with a drug. Black box warnings are supposed to provide physicians with important insights as to how to prescribe a drug that may be associated with serious side effects in a way that maximizes its benefits and minimizes its risks.

The addition of the black box warning came as a result of the drug manufacturer's and FDA's analysis of data that clarified the drug's long-term effects on bone density.

In addition to the black box warning on the labeling, the drug's manufacturer will issue a "Dear Health Care Practitioner" letter regarding the effect of long-term treatment on bone mineral density to health care professionals likely to prescribe the drug, and will incorporate the new information in the patient information sheet distributed with the drug.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.

Back to the top |

Terms of Use Your use of this site constitutes acceptance of the Terms of Use

Advertisements on this site are placed and controlled by outside advertising networks. ConsumerAffairs.com does not evaluate or endorse the products and services advertised. See the FAQ for more information.

Company Response Welcome If complaints about your company appear on our site, we welcome your response. Please see the Response Form for more information.

For more information, see the FAQ and privacy policy. The information on this Web site is general in nature and is not intended as a substitute for competent legal advice.  ConsumerAffairs.com Inc. makes no representation as to the accuracy of the information herein provided and assumes no liability for any damages or loss arising from the use thereof. 

Copyright © 2003-2009 ConsumerAffairs.com Inc.  All Rights Reserved.    The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission.